Fig. 3.

COVID-19 vaccine development landscape: five main technologies and 44 candidates in human clinical trials. Courtesy of M. Saville. Legend: The COVAX R&D&M portfolio consists of 9 candidate vaccines in clinical development. As presented on 05th November, from 44 known COVID-19 candidate vaccines in clinical trials, the COVAX R&D portfolio consists of 9 candidate vaccines in clinical development supported by CEPI (boxes with black frame), whereby 3 have reached phase 3 trials. These candidates, based on multiple technology platforms and diversified across geographies contribute to minimize the risks of hampering global distribution by export and controls of countries hosting manufacturing. Cf. https://cepi.net/research_dev/our-portfolio/